About ArthroCare (NASDAQ:ARTC)
ArthroCare Corporation (ArthroCare) is a medical device company. ArthroCare develops and manufactures surgical devices, instruments, and implants. Its devices enable surgical procedures and enable new minimally invasive procedures. Many of ArthroCare's devices use its Coblation technology. This technology dissolves target tissue and limits damage to surrounding healthy tissue. ArthroCare also develops surgical devices utilizing other patented technology, including its OPUS line of fixation products, as well as re-usable surgical instruments. ArthroCare's two core product consists of sports medicine and ear, nose, and throat (ENT), as well as other areas, such as spine, wound care, urology and gynecology. It's Sports Medicine, ENT and other products are marketed and sold through two principal geographic distribution channels: Americas (North and South America) and International (all other geographies). In May 2014, Smith & Nephew PLC acquired the Company.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Health Care Equipment & Supplies
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:ARTC
- CUSIP: 04313610
- Web: N/A
- 50 Day Moving Avg: $3.00
- 200 Day Moving Avg: $4.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 30.57
- P/E Growth: 0
Frequently Asked Questions for ArthroCare (NASDAQ:ARTC)
What is ArthroCare's stock symbol?
ArthroCare trades on the NASDAQ under the ticker symbol "ARTC."
Who are some of ArthroCare's key competitors?
Some companies that are related to ArthroCare include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), VCA (WOOF), NMC Health PLC (NMC), Valeant Pharmaceuticals Intl (VRX), Catalent (CTLT), Health Net (HNT), Patheon NV (PTHN), Mediclinic International PLC (MDC), Puma Biotechnology (PBYI), BIO-TECHNE Corp (TECH), Alere (ALR) and ConvaTec Group PLC (CTEC).
How do I buy ArthroCare stock?
Shares of ArthroCare can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ArthroCare's stock price today?
MarketBeat Community Rating for ArthroCare (NASDAQ ARTC)MarketBeat's community ratings are surveys of what our community members think about ArthroCare and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of ArthroCare stock can currently be purchased for approximately $48.60.
Consensus Ratings for ArthroCare (NASDAQ:ARTC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for ArthroCare (NASDAQ:ARTC)
Analysts' Ratings History for ArthroCare (NASDAQ:ARTC)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for ArthroCare (NASDAQ:ARTC)Earnings History by Quarter for ArthroCare (NASDAQ ARTC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/2/2014||Q313||$0.35||$0.32||$96.00 million||$96.06 million||View||N/A|
|2/13/2014||Q213||$0.40||$0.30||$100.53 million||$101.70 million||View||N/A|
|8/5/2013||Q2 2013||$0.34||($0.27)||$93.67 million||$92.10 million||View||Listen|
|5/7/2013||Q1 2013||$0.37||$0.30||$94.41 million||$92.30 million||View||Listen|
|2/13/2013||Q4 2012||$0.37||$0.30||$93.78 million||$96.90 million||View||Listen|
Earnings Estimates for ArthroCare (NASDAQ:ARTC)
Current Year EPS Consensus Estimate: $1.51 EPS
Next Year EPS Consensus Estimate: $1.59 EPS
Dividend History for ArthroCare (NASDAQ:ARTC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ArthroCare (NASDAQ:ARTC)Insider Trades by Quarter for ArthroCare (NASDAQ:ARTC)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|1/9/2014||Jean Woloszko||SVP||Sell||32,627||$45.67||$1,490,075.09|| |
|1/8/2014||Barbara Boyan||Director||Sell||10,000||$45.00||$450,000.00|| |
|1/8/2014||Bruce Prothro||SVP||Sell||33,478||$45.82||$1,533,961.96|| |
|1/6/2014||Bruce Prothro||SVP||Sell||6,167||$39.75||$245,138.25|| |
|12/19/2013||Barbara Boyan||Director||Sell||10,000||$40.00||$400,000.00|| |
|12/19/2013||Jean Woloszko||SVP||Sell||10,657||$39.98||$426,066.86|| |
|10/30/2013||Jean Woloszko||SVP||Sell||1,342||$37.95||$50,928.90|| |
|10/7/2013||James Pacek||SVP||Sell||2,500||$34.48||$86,200.00|| |
|6/18/2013||Bruce Prothro||SVP||Sell||2,512||$36.00||$90,432.00|| |
|5/24/2013||Peter Wilson||Director||Sell||10,000||$33.36||$333,600.00|| |
|11/13/2012||David Fitzgerald||Director||Sell||25,000||$31.34||$783,500.00|| |
|8/7/2012||James G Foster||Director||Sell||35,000||$28.81||$1,008,350.00|| |
Headline Trends for ArthroCare (NASDAQ:ARTC)
Latest Headlines for ArthroCare (NASDAQ:ARTC)
No headlines for this company have been tracked by MarketBeat.com
ArthroCare (ARTC) Chart for Wednesday, October, 18, 2017